Global search

Find data and evidence

Type at least 2 characters. Use arrow keys to review and Enter to open.

Peer reviewedOpen accessTuberculosis

Analytical performance of a multi-target open real-time PCR assay for simultaneous detection of tuberculosis, non-tuberculous mycobacteria, and drug resistance in a high-burden setting.

Microbiology spectrum·

Sidiq Z, Anand A, Tyagi P, Dwivedi KK, Rajpal S, Chopra KK

DOI
10.1128/spectrum.01643-26
PMID
42603138
PMCID
OpenAlex
W7155552823
Study type
Journal article
Publisher
Publisher unavailable
Article type
journal-article
Integrity
current

Why this research matters now

Multi-target molecular platforms that detect both rifampicin and isoniazid resistance address current diagnostic gaps where rifampicin serves as the sole surrogate for multidrug resistance. The open-platform design may offer flexibility and reduced dependence on proprietary systems in high-burden settings.

01

Structured evidence summary

Research question

The study evaluated the analytical performance of two multiplex real-time PCR assays for concurrent detection of Mycobacterium tuberculosis complex, non-tuberculous mycobacteria, and resistance to rifampicin and isoniazid.

Study design

Analytical validation study using 300 well-characterized samples (150 MTBc-positive, 150 MTBc-negative) with composite reference standards including culture, MPT64 antigen testing, line probe assays, and phenotypic drug susceptibility testing.

Population and setting

The study was conducted in a high-burden tuberculosis setting using characterized culture isolates.

Main findings

MTBc detection achieved 100% sensitivity and specificity. NTM detection showed 70.0% sensitivity and 100% specificity. Rifampicin resistance detection demonstrated 96.0% sensitivity and 100% specificity, while isoniazid resistance detection achieved 100% for both measures. Agreement with reference standards was high (κ = 0.76-1.00).

Public-health relevance

Multi-target molecular platforms that detect both rifampicin and isoniazid resistance address current diagnostic gaps where rifampicin serves as the sole surrogate for multidrug resistance. The open-platform design may offer flexibility and reduced dependence on proprietary systems in high-burden settings.

Important limitations

NTM species coverage was incomplete. The study was an analytical validation using culture isolates rather than clinical specimens. Clinical validation, cost-effectiveness analysis, and operational feasibility studies have not yet been conducted.

GIDS interpretation

The article was identified through classifier links for tuberculosis diagnostics and treatment topics. It describes a laboratory validation study of a diagnostic technology rather than epidemiologic surveillance data.

02

Related GIDS surveillance

Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.

03

Evidence relationships

This article has 7 auditable classifier relationships to diseases, places, topics, and study design.

about diseaseaddresses topicaddresses topicevaluates interventionevaluates interventionstudied population settinguses study design